ABSTRACT Angiogenesis and RAS/RAF/MEK/ERK pathway have been demonstrated to be
relevant in hepatocellular carcinoma (HCC). Sorafenib, an oral multikinase inhibitor with …

Hepatocellular Carcinoma: A Prospective Multicenter Study in Italy” by Iavarone et al. was
published in this journal. 1 To date, the conclusions of this article continue to stimulate …

BACKGROUND: Sorafenib is currently the only approved systemic treatment for
hepatocellular carcinoma. AIM: to evaluate safety and effectiveness of sorafenib in the field …

The efficacy of sorafenib against hepatocellular carcinoma (HCC) has been extensively
reported. However, there is little information available about the use of sorafenib for HCC …

Objective. Sorafenib has been shown to improve survival of patients with advanced
hepatocellular carcinoma (HCC). However, its tolerance in clinical practice has not been …

Purpose Sorafenib is a multikinase inhibitor used for treatment of advanced hepatocellular
carcinoma. Sorafenib resistance may be related to Src-induced cell migration and …

Purpose: Cancer cell survival, invasion, and metastasis depend on cancer cell proliferation
and on tumor-induced angiogenesis. We evaluated the efficacy of the combination of …

Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced
hepatocellular carcinoma (HCC). The present study was undertaken to determine whether …

Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of
advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib …

Background/Aim: Sorafenib is the medical reference for treatment of hepatocellular
carcinoma (HCC). Multiple forms of cytotoxicity are induced by sorafenib in HCC cells in vitro …